Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.63 |
| ▸ | CRHR1 | P34998 | 16/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 3/20 | 0.45 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13717339 | 1.00 | CNR1 (0.63) | CNR1CRHR1CRHR2CNR2MEN1 | |
| SCHEMBL3928194 | 0.95 | CNR1 (0.66) | CNR1CRHR1CRHR2CNR2MEN1 | |
| SCHEMBL3916898 | 0.89 | CNR1 (0.60) | CNR1CRHR1CRHR2CNR2MEN1 | |
| SCHEMBL3916901 | 0.89 | CNR1 (0.60) | CNR1CRHR1CRHR2CNR2MEN1 | |
| SCHEMBL13717335 | 0.89 | CNR1 (0.60) | CNR1CRHR1CRHR2CNR2MEN1 | |
| SCHEMBL5570586 | 0.89 | CNR1 (0.60) | CNR1CRHR1CRHR2CNR2MEN1 | |
| SCHEMBL3919720 | 0.88 | CNR1 (0.64) | CNR1CRHR1CRHR2MEN1ALDH1A1 | |
| SCHEMBL13717094 | 0.88 | CNR1 (0.79) | CNR1CRHR1CRHR2CNR2 | |
| SCHEMBL3927712 | 0.88 | CNR1 (0.78) | CNR1CRHR1CRHR2 | |
| SCHEMBL13717181 | 0.87 | CNR1 (0.83) | CNR1CRHR1CRHR2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579369-B2 | CB 1 receptor inverse agonists | HOFFMANN-LA ROCHE INC. (US) | 2009-08-25 | — | — | US | claimed |
| EP-1583742-B1 | CB 1 RECEPTOUR INVERSE AGONISTS | HOFFMANN LA ROCHE (CH) | 2009-12-02 | — | — | EP | disclosed |
| US-7579369-B2 | CB 1 receptor inverse agonists | HOFFMANN-LA ROCHE INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7294644-B2 | CB 1 receptor inverse agonists | HOFFMANN-LA ROCHE INC. (US) | 2007-11-13 | — | — | US | disclosed |
| US-20070238754-A1 | Novel CB 1 receptor inverse agonists | MAYWEG ALEXANDER | 2007-10-11 | — | — | US | disclosed |
| EP-1583742-A1 | NOVEL CB 1 RECEPTOUR INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-12 | — | — | EP | disclosed |
| US-20040167129-A1 | Novel CB 1 receptor inverse agonists | HOFFMANN-LA ROCHE INC. | 2004-08-26 | — | — | US | disclosed |
| WO-2004060870-A1 | NOVEL CB 1 RECEPTOUR INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167129-A1 | Novel CB 1 receptor inverse agonists | CNR1, CNR2, ARRB1 | CNR1 1/4885CRHR1 11/4885CRHR2 47/4885 |
| US-20070238754-A1 | Novel CB 1 receptor inverse agonists | CNR1, CNR2, GPR139 | CNR1 1/4885CRHR1 12/4885CRHR2 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.